title: Deficiency in asparagine synthetase expression in rectal cancers receiving concurrent chemoradiotherapy: negative prognostic impact and therapeutic relevance.
abstract: Locally advanced rectal cancers are currently treated with neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery, but risk stratification and final outcomes remain suboptimal. In this study, we identify and validate targetable metabolic drivers relevant to the prognosis of patients with rectal cancer treated with CCRT. Using a published transcriptome of rectal cancers, we found that asparagine synthetase (ASNS) gene significantly predicted the response to CCRT. From 172 patients with rectal cancer, the expression levels of ASNS, using immunohistochemistry assays, were further evaluated in tumor specimens initially obtained by using colonoscopy. Expression levels of ASNS were further correlated with major clinicopathological features and clinical survivals in this valid cohort. ASNS deficiency was significantly related to advanced posttreatment tumor (T3, T4; P = .015) and nodal status (N1, N2; P = .004) and inferior tumor regression grade (P < .001). In survival analyses, ASNS deficiency was significantly associated with shorter local recurrence-free survival (LRFS; P = .0039), metastasis-free survival (MeFS; P = .0001), and disease-specific survival (DSS; P = .0006). Furthermore, ASNS deficiency was independently predictive of worse outcomes for MeFS (P = .012, hazard ratio = 3.691) and DSS (P = .022, hazard ratio = 2.845), using multivariate analysis. ASNS deficiency is correlated with poor therapeutic response and worse survivals in patients with rectal cancer receiving neoadjuvant CCRT. These findings indicate that ASNS is a prognostic factor with therapeutic potential for treating rectal cancer.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Foundation Medical Center, Tainan, Taiwan.
authors.forename: Ching-Yih
authors.initials: CY
authors.lastname: Lin
authors.forename: Ming-Jen
authors.initials: MJ
authors.lastname: Sheu
authors.forename: Chien-Feng
authors.initials: CF
authors.lastname: Li
authors.forename: Sung-Wei
authors.initials: SW
authors.lastname: Lee
authors.forename: Li-Ching
authors.initials: LC
authors.lastname: Lin
authors.forename: Yi-Fong
authors.initials: YF
authors.lastname: Wang
authors.forename: Shang-Hung
authors.initials: SH
authors.lastname: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001217:Aspartate-Ammonia Ligase / Q000096:biosynthesis* / Q000235:genetics; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000235:genetics / Q000532:radiotherapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D001217:Aspartate-Ammonia Ligase
references.citation: Tumour Biol. 2014 Jan;35(1):161-9
references.pmid: 23897555
references.citation: Cancer. 1971 Oct;28(4):819-24
references.pmid: 5286444
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Clin Cancer Res. 2013 Jun 1;19(11):2861-72
references.pmid: 23549872
references.citation: Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E789-99
references.pmid: 23403946
references.citation: Cancer. 2003 Jan 15;97(2):517-24
references.pmid: 12518377
references.citation: N Engl J Med. 2006 Sep 14;355(11):1114-23
references.pmid: 16971718
references.citation: Nat Genet. 2001 Nov;29(3):263-4
references.pmid: 11687795
references.citation: J Clin Oncol. 2006 Oct 1;24(28):4620-5
references.pmid: 17008704
references.citation: Pancreas. 2012 Aug;41(6):940-8
references.pmid: 22513289
references.citation: Annu Rev Biochem. 2006;75:629-54
references.pmid: 16756505
references.citation: Mol Cancer Ther. 2008 Oct;7(10):3123-8
references.pmid: 18852115
references.citation: Mol Cancer Ther. 2013 Oct;12(10):2157-66
references.pmid: 23956056
references.citation: Cancer Res. 1971 Jul;31(7):942-9
references.pmid: 4327086
references.citation: N Engl J Med. 2004 Oct 21;351(17):1731-40
references.pmid: 15496622
references.citation: Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):664-74
references.pmid: 12062610
references.citation: Br J Cancer. 2013 Jul 9;109(1):14-23
references.pmid: 23764751
references.citation: J Nutr. 2002 Jul;132(7):1801-4
references.pmid: 12097650
references.citation: N Engl J Med. 2006 Jan 12;354(2):166-78
references.pmid: 16407512
references.citation: Tumour Biol. 2013 Apr;34(2):1107-17
references.pmid: 23328995
references.citation: Blood. 2006 Jun 1;107(11):4244-9
references.pmid: 16497975
references.citation: Nat Rev Cancer. 2011 Feb;11(2):85-95
references.pmid: 21258394
references.citation: Nat Rev Cancer. 2010 Apr;10(4):267-77
references.pmid: 20300106
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8688-96
references.pmid: 16246976
references.citation: Dis Colon Rectum. 2001 Apr;44(4):513-22
references.pmid: 11330578
references.citation: Int J Colorectal Dis. 1997;12(1):19-23
references.pmid: 9112145